CSF3 and breast carcinoma: Several international guidelines, including the American Society of Clinical Oncology (ASCO), recommend granulocyte colony-stimulating factor (G-CSF) and/or antimicrobial agents for breast cancer patients with febrile neutropenia risk to avoid sepsis and severe infection that can result in patient morbidity and mortality [42, 43].